Arcadia Biosciences, Inc. (RKDA)

NASDAQ: RKDA · IEX Real-Time Price · USD

2.030

+0.080 (4.10%)

At close: Apr 17, 2024, 4:00 PM

2.160

+0.130 (6.41%)

Pre-market: Apr 18, 2024, 7:08 AM EDT

Arcadia Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Net Income	-13.98	-15.38	-14.66	-4.66	-28.81	-13.48	-15.71	-19.62	-20.73	-22.08	Upgrade
Depreciation & Amortization	0.98	1.36	2.32	1.71	0.9	0.15	0.28	0.3	0.29	0.36	Upgrade
Share-Based Compensation	0.72	1.11	1.54	2.04	2.29	1.55	1.47	1.06	1.39	1.07	Upgrade
Other Operating Activities	-3.01	-1.07	-15.07	-29.32	8.42	-1.86	-0.01	1.21	1.16	2.13	Upgrade
Operating Cash Flow	-15.29	-13.98	-25.87	-30.22	-17.2	-13.63	-13.97	-17.06	-15.11	-14.79	Upgrade
Capital Expenditures	0.11	0.85	-0.99	-2.33	-1.46	-0.24	-0.08	-0.23	-0.14	-0.14	Upgrade
Acquisitions	0.57	0.57	-4.25	2.65	0	0	0	0	0	0	Upgrade
Change in Investments	-5.02	0	21.85	16.96	-6.91	-5.74	47.25	-5.07	-46.22	-1.45	Upgrade
Investing Cash Flow	-4.34	1.42	16.61	17.28	-8.37	-5.98	47.18	-5.3	-46.36	-1.59	Upgrade
Share Issuance / Repurchase	6.01	5.01	25.17	16.51	22.77	22.69	0	0	68.23	0.02	Upgrade
Debt Issued / Paid	0	0	-2.15	3.07	-0.01	0	-26.13	-0.05	8.49	-1.16	Upgrade
Other Financing Activities	-0.5	-0.49	-1.12	0.98	-0.78	-0.21	0.02	0.44	-7.85	31.25	Upgrade
Financing Cash Flow	5.51	4.52	21.9	20.56	21.99	22.48	-26.1	0.4	68.87	30.11	Upgrade
Exchange Rate Effect	0	0	0	0	0	0	0	0	0	0	Upgrade
Net Cash Flow	-14.13	-8.04	12.64	7.63	-3.58	2.87	7.11	-21.96	7.4	13.74	Upgrade
Free Cash Flow	-15.18	-13.13	-26.86	-32.55	-18.66	-13.87	-14.04	-17.29	-15.25	-14.93	Upgrade
Free Cash Flow Margin	-284.88%	-176.99%	-396.11%	-405.09%	-1596.15%	-947.47%	-348.73%	-542.22%	-281.68%	-213.81%	Upgrade
Free Cash Flow Per Share	-12.28	-21.90	-50.48	-130.72	-117.30	-147.31	-260.46	-311.69	-427.18	-5793.69	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).